Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Naoki Tanaka

Professor

Shinshu University School of Medicine

Japan

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Biochemistry

20%

Clinical Nutrition

50%

Fatty Liver

60%

Inflammatory Biology

30%

Enzyme Replacement Therapy

30%

Nafld

20%

Metabolic Biology

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles11

Investigation of Clinical Features and Association between Vascular Endothelial Injury Markers and Cytomegalovirus Infection Associated with Thrombotic Microangiopathy in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis: Case-Based Research

Article Link

Year:

2024

An Orally Deliverable Ornithine-Based Self-Assembling Polymer Nanomedicine Ameliorates Hyperammonemia in Acetaminophen-Induced Acute Liver Injury

Article Link

Year:

2023

Establishment of Novel Mouse Model of Dietary NASH Rapidly Progressing into Liver Cirrhosis and Tumors

Article Link

Year:

2023

Citrin Deficiency: Clinical and Nutritional Features

Article Link

Year:

2023

Resmetirom Ameliorates NASH-Model Mice by Suppressing STAT3 and NF-κB Signaling Pathways in an RGS5-Dependent Manner

Article Link

Year:

2023

Development of the Rabbit NASH Model Resembling Human NASH and Atherosclerosis

Article Link

Year:

2023

Pemafibrate for primary biliary cholangitis with dyslipidemia: A proposal of a new treatment from Japan.

Article Link

Year:

2022

Serum Sulfatide Levels as a Biomarker of Active Glomerular Lesion in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Single Center Pilot Study

Article Link

Year:

2022

Higher Responsiveness for Women, High Transaminase Levels, and Fat Percentage to Pemafibrate Treatment for NAFLD

Article Link

Year:

2022

Clinically Relevant Dose of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα), Lowers Serum Triglyceride Levels by Targeting Hepatic PPARα in Mice

Article Link

Year:

2022

2‐Step PLT16‐AST44 method: Simplified liver fibrosis detection system in patients with non‐alcoholic fatty liver disease

Article Link

Year:

2022

Collaborators6

Daiki Aomura

Shinshu University Hospital

JAPAN

Akira Honda

University of Tokyo Hospital

JAPAN

Yuji Kamijo

Shinshu University School of Medicine

JAPAN

Masahide Yazaki

Shinshu University

JAPAN

Takeji Umemura

Shinshu University School of Medicine

JAPAN

Takanobu Iwadare

Shinshu University

JAPAN

How do I reach out?

Meet Kite AI